WALTHAM, Mass, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced the Company’s participation at the following healthcare investor conferences:
- Guggenheim’s Inaugural Healthcare Innovation Conference on November 12, 2024, in Boston, MA
- Jefferies London Healthcare Conference on November 19, 2024 presentation at 4:00 p.m. to 4:25 p.m. GDT, in London
- Citi’s 2024 Global Healthcare Conference on December 3, 2024 presentation at 9:30 a.m. to 10:10 a.m. ET, in Miami, FL
- Evercore ISI HealthCONx Conference on December 4, 2024 presentation at 1:20 p.m. to 1:40 p.m. ET, in Coral Gables, FL
Live webcasts and archived replays of the Company’s presentations at the Jefferies, Citi and Evercore conferences can be accessed under “Events and Presentations” in the Investors and Media section of the Zenas BioPharma website.
About Zenas BioPharma, Inc.
Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative immunology-based therapies for patients in need. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas’ lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab’s mechanism of action and chronic dosing regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on X at @ZenasBioPharma and LinkedIn.
The Zenas BioPharma word mark and logos are trademarks of Zenas BioPharma, Inc. or its affiliated companies.
Investor Contact:
Matthew Osborne
Investor Relations and Corporate Communications
Matt.osborne@zenasbio.com
Media Contact:
Argot Partners
Zenas@argotpartners.com
-
Zenas BioPharma to Participate in Upcoming Healthcare Investor ConferencesWALTHAM, Mass, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopha2024-11-07
-
ATNi Launches 5th Global Access to Nutrition Index as Industry and Policy Makers Grapple with Food PUTRECHT, The Netherlands, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Today, ATNi launches the 5th edition of the Global Access to Nutrition Index, the largest2024-11-07
-
ATNi 发布第 5 版全球营养获取指数,助力行业与政策制定者应对食品多重危机乌特勒支,荷兰, Nov. 07, 2024 (GLOBE NEWSWIRE) -- 今日,ATNi 发布了第五版全球营养获取指数,这是迄今为止规模最大的版次,评估了全球 30 家大型食品和饮料制造商及2024-11-07
-
MLL Legal Selects Anaqua’s AQX Law Firm Platform to Enhance IP Management and Drive Operational EffiLeading Swiss law firm adopts scalable, intuitive solution to strengthen IP management capabilities BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Anaqu2024-11-07
-
广西以进博为桥 与世界互惠共赢“博”采众长,满是“七”待。11月5日至10日,第七届中国国际进口博览会(下文简称“进博会”)在上海举行。作为连续七年参展进博会的“全勤生”,进博会已成为广西面向全2024-11-07